Across 9 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Colgate-Palmolive Company news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 18 points from the previous 30 days (+26).
📈 India revenue rose 12.2% YoY to INR 1,705.7 crore in Q3 2026.
⚠️ EBITDA margin fell to 28% as brand spending outpaced earnings growth.
Bullish +65
Colgate-Palmolive India stock set for INR 24 interim dividend
AI-generated analysis
Key insights
📈 Colgate-Palmolive India reported a 12.2% year-over-year increase in revenue from operations, reaching INR 1,705.7 crore for the quarter ended September 30, 2026.
💰 Net profit grew 4.2% to INR 342 crore, demonstrating resilient profitability despite macroeconomic headwinds in the Indian consumer market.
🦷 The toothpaste portfolio achieved high-single-digit volume growth, bolstered by the premium range and the launch of Colgate MaxFresh.
⚠️ EBITDA margin declined to 28% from 31% as increased spending on brand building and premiumisation outpaced earnings growth in the quarter.
💸 Gross margin expanded by 40 basis points to 69.6%, indicating effective pricing power despite rising commodity costs.
📅 The company's board approved an interim dividend of INR 24 per share for fiscal 2026-27, payable starting November 19, 2026.
🏢 Management plans to mitigate commodity-cost volatility through cost savings initiatives and calibrated pricing strategies moving forward.
📈 Bullish signals
📈Colgate-Palmolive India delivered a strong quarterly performance with net profit rising 4.2% year over year to INR 342 crore.
📈Revenue from operations surged 12.2% to INR 1,705.7 crore, driven by double-digit sales growth in the core toothpaste portfolio.
🦷The company successfully launched Colgate MaxFresh and expanded its premium range, contributing to high-single-digit volume growth.
💸Gross margins improved by 40 basis points to 69.6%, reflecting effective cost management and pricing strategies.
📅The board approved a substantial interim dividend of INR 24 per share, signaling confidence in future cash flows.
📉 Risk factors
⚠️EBITDA margin contracted to 28% from 31% due to higher brand-building and premiumisation spending that outpaced earnings growth.
💰Operating costs and investment spending grew faster than earnings, temporarily dampening overall profitability despite revenue expansion.
Article
Colgate-Palmolive India reported robust financial performance for the quarter ended September 30, 2026, driven by double-digit sales growth and a strong profit beat. Net profit rose 4.2% year over year to INR 342 crore, while revenue from operations increased 12.2% to INR 1,705.7 crore. The company's toothpaste portfolio delivered high-single-digit volume growth, supported by the premium range and the Colgate MaxFresh product line.
Despite the top-line strength, operating efficiency faced headwinds as higher spending on brand building and premiumisation squeezed the EBITDA margin to 28% from 31%. Gross margins expanded by 40 basis points to 69.6%, but management noted that operating costs and investment spending grew faster than earnings. The company plans to address commodity-cost volatility through cost savings and calibrated pricing while continuing to invest in products and advertising.
The board approved an interim dividend of INR 24 per share for fiscal 2026-27, with payments scheduled to begin on November 19, 2026. Shareholders recorded on November 2, 2026, are eligible for this payout. This announcement follows the company's strong quarterly results and reflects its commitment to returning value to shareholders while navigating input cost pressures in the Indian consumer staples market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Colgate-Palmolive shares recently gained value supported by a newly declared quarterly dividend of $0.53 per share, announced on September 17, 2026. This payout establishes a forward dividend yield of 2.42 percent based on the stock's trading price near $87.73. The company maintains an impressive track record of uninterrupted dividend payments dating back to 1895, reinforcing its status as a reliable income generator within the consumer staples sector.
Analyst data from GuruFocus indicates that Colgate-Palmolive is currently trading at approximately 8 percent below its estimated fair value of $95.34 per share. While the trailing price-to-earnings ratio stands at 34.7 times, which is slightly elevated compared to the company's five-year median of 31.58 times, the undervaluation relative to the GF Value metric suggests a modest buying opportunity for investors.
The declared dividend will be payable on November 13, 2026, to shareholders of record as of October 20, 2026. The payout ratio is estimated at about 55 percent, and the company has demonstrated consistent annual dividend growth averaging 3.5 percent over the past three years, signaling continued commitment to returning cash to shareholders.
💰 Company maintains uninterrupted dividend history since 1895 for income investors.
📊 GuruFocus fair value of $95.34 suggests shares near $87.73 are 8% undervalued.
📉 Trailing P/E of 34.7x is slightly above five-year median of 31.58x.
📅 Record date Oct 20, 2026; payment date Nov 13, 2026 for shareholders.
📈 Colgate-Palmolive declared a quarterly cash dividend of $0.53 per share on September 17, 2026, supporting a forward yield of 2.42 percent.
💰 The company has maintained an uninterrupted history of dividend payments since 1895, appealing to income-focused investors.
📊 GuruFocus estimates the stock's fair value at $95.34, suggesting shares trading near $87.73 are roughly 8 percent undervalued.
📉 The trailing P/E ratio of 34.7 times is slightly above the five-year median of 31.58 times, indicating a modest valuation premium.
📅 Shareholders of record on October 20, 2026, will receive the dividend payment on November 13, 2026.
📈 The payout ratio is approximately 55 percent, with annual dividend growth averaging 3.5 percent over the last three years.
Bullish Signals
Quarterly dividend declared at $0.53/share with 2.42% yield.
Risk Factors
Stock trades at 34.7x P/E vs 31.58x five-year median.
Bullish Signals
Colgate-Palmolive declared a quarterly cash dividend of $0.53 per share, establishing a forward yield of 2.42 percent based on the current trading price.
The company boasts an uninterrupted dividend payment history dating back to 1895, reinforcing its reliability as a consumer staples stock.
Analyst estimates suggest the stock is trading approximately 8 percent below its calculated fair value of $95.34 per share.
Colgate-Palmolive has demonstrated consistent dividend growth, averaging 3.5 percent annually over the past three years.
Risk Factors
The stock trades at a trailing P/E ratio of 34.7 times, which is slightly higher than its five-year median of 31.58 times, indicating a modest valuation premium.
Colgate-Palmolive (CL) is exploring the sale of several mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, in a strategic effort to streamline its portfolio. The company is reportedly working with Goldman Sachs on this potential divestiture, which could generate proceeds exceeding $1 billion. Personal care currently accounts for approximately 17% of the company's net sales, representing roughly $3.5 billion in revenue for 2025.
The move addresses competitive pressure within Colgate-Palmolive's North American business, where organic sales declined by 3% despite a reported 4.9% increase in total net sales. By divesting these brands, management aims to concentrate capital, marketing, and attention on higher-growth categories such as oral care and pet nutrition. This strategy aligns with a broader industry trend among major consumer goods companies like Unilever and Nestlé to simplify portfolios and focus on core competitive advantages.
Analysts view the potential divestiture as moderately bullish if executed at attractive valuations, as it would unlock capital for debt reduction, share repurchases, or reinvestment in high-growth areas. However, risks include the possibility that the brands are being sold due to underperformance rather than strategic non-core status, and concerns that a disappointing valuation could force Colgate to accept lower prices. Additionally, the broader consumer environment faces headwinds from rising costs and price-sensitive consumers, which could complicate the timing of such sales.
Ultimately, the success of this portfolio reshaping depends on whether Colgate can replace the divested revenue with sustainable organic growth and margin improvements. If the company fails to demonstrate stronger growth in its remaining segments, investors may view the restructuring as merely offsetting weak performance rather than driving future value creation.
📉 CL explores selling Softsoap/Irish Spring brands for over $1B proceeds.
📊 Personal care segment accounts for 17% of CL's 2025 net sales.
📉 North American organic sales declined 3% amid competitive pressure.
🎯 CL will focus capital on oral care and pet nutrition growth.
⚠️ Divestiture risks modest valuation if buyers view assets as declining.
📉 Colgate-Palmolive is exploring the sale of mass-market personal care brands like Softsoap and Irish Spring to streamline its portfolio.
💰 The potential divestiture could generate more than $1 billion in proceeds, providing capital for debt reduction or share repurchases.
📊 Personal care represents roughly 17% of Colgate-Palmolive's 2025 net sales, totaling approximately $3.5 billion.
📉 North American organic sales declined 3%, highlighting competitive pressure in a mature market that the company aims to address.
🤝 The company is working with Goldman Sachs on the potential divestiture of these specific brands.
🎯 Management intends to concentrate capital and marketing efforts on higher-growth categories like oral care and pet nutrition.
📉 Industry peers such as Unilever and Nestlé are similarly shedding slower-growing businesses to focus on core strengths.
⚠️ There is a risk that the brands being sold are underperforming rather than genuinely non-core to the business strategy.
💸 If buyers perceive the assets as declining, Colgate could be forced to accept a modest valuation for the divestiture.
📉 Rising commodity costs and price-sensitive consumers create a challenging environment for executing these sales effectively.
🔄 Portfolio restructuring alone may not solve underlying growth problems if North American organic sales continue to decline.
Bullish Signals
Sale generates >$1B for debt reduction or buybacks.
Focus capital on higher-growth oral care and pet nutrition.
Strategy aligns with industry trend to simplify portfolios.
Risk Factors
North American organic sales declined 3% amid competitive pressure.
Brands may underperform, risking future cash flows from non-core assets.
Low valuation could force asset sales at reduced prices.
High costs and price-sensitive consumers hinder divestiture execution.
Bullish Signals
The potential sale of personal care brands could generate more than $1 billion in proceeds, providing significant capital for debt reduction or share repurchases.
Divesting non-core assets allows management to concentrate marketing spending and capital on higher-growth categories like oral care and pet nutrition.
The strategy aligns with a broader industry trend among major consumer goods companies to simplify portfolios and focus on core competitive advantages.
Risk Factors
North American organic sales declined 3%, indicating significant competitive pressure in the company's largest market.
There is a risk that the brands being sold are underperforming rather than strategically non-core, potentially sacrificing future cash flows.
A disappointing valuation could force Colgate to accept lower prices for assets that represent a meaningful portion of its personal-care business.
Rising commodity and energy costs combined with price-sensitive consumers create a difficult environment for executing divestitures at peak value.
Colgate-Palmolive has received a buy rating upgrade from analysts driven by the return of organic sales growth and robust profitability that currently leads its sector. The company's recent performance indicates a stabilization in its core business metrics, with organic sales growth specifically noted at 2.4%.
This positive momentum is further supported by the company's 2026 guidance, which is approaching its long-term targets. Analysts view this convergence of current operational strength and future outlook as a key driver for optimism regarding the stock's valuation multiples.
📈 CL upgraded to buy after organic sales growth returns.
💰 CL shows strong profitability leading sector peers.
🎯 CL 2026 guidance nearing long-term targets.
📊 CL organic sales growth returned at 2.4%.
📈 Colgate-Palmolive has been upgraded to a buy rating following a return in organic sales growth.
💰 The company demonstrates strong profitability that currently leads its sector peers.
🎯 2026 guidance is nearing long-term targets, supporting optimism for stock multiples.
📊 Organic sales growth has returned at a rate of 2.4%.
Colgate-Palmolive (CL) stock declined following confirmation by S&P Dow Jones Indices that the consumer products group will be removed from the S&P 100 index ahead of a quarterly rebalancing scheduled for September 21, 2026. The reshuffle reflects a broader market shift where mega-cap benchmarks are tilting away from traditional consumer staples toward high-growth AI infrastructure plays, causing CL to slip out of the very top market-cap bracket represented by the index.
Despite the index removal, Colgate-Palmolive remains a relatively expensive defensive stock with a price-to-earnings ratio of 35.23 times trailing twelve-month earnings, compared to a five-year median of 31.26 times. While the company trades at a premium versus its historical multiple, GuruFocus data suggests a modest single-digit percentage undervaluation relative to its proprietary GF Value estimate, indicating mixed valuation signals for investors.
The removal from the S&P 100 will likely trigger mechanical selling by passive index and ETF products, such as the iShares S&P 100 ETF where CL previously represented about 0.16 percent of fund assets. However, the impact is constrained by the stock's already low weight in the fund, with Colgate-Palmolive and Nike together accounting for only 0.27 percent before their removal.
Colgate-Palmolive continues to generate resilient cash flows from its global oral care franchise, which includes toothpaste, toothbrushes, and mouthwash products built around the Colgate brand. As of September 4, 2026, the share price stood at USD 88.77, placing it modestly lower than technology peers that have posted significantly larger year-to-date gains.
📉 S&P 100 removal confirmed for CL before Sept 21, 2026.
💰 CL trades at 35.23x earnings, above its 5-year median of 31.26x.
💵 CL shares fell to USD 88.77 on reshuffle headlines.
🛡️ Global oral care franchise provides resilient cash flows for CL.
📉 S&P Dow Jones Indices confirmed Colgate-Palmolive will be removed from the S&P 100 index prior to the opening of US markets on September 21, 2026.
💰 The company trades at a price-to-earnings ratio of 35.23 times trailing twelve-month earnings, which is above its five-year median of 31.26 times.
📊 Colgate-Palmolive previously represented about 0.16 percent of assets in the iShares S&P 100 ETF before the index rebalancing.
💵 As of September 4, 2026, Colgate-Palmolive's share price stood at USD 88.77 following the stock's decline on reshuffle headlines.
🛡️ The company generates significant revenue from its global oral care franchise built around the Colgate brand, providing resilient cash flows.
🤖 The index reshuffle highlights how benchmarks are shifting away from consumer staples toward high-growth AI infrastructure plays like Dell Technologies and Palo Alto Networks.
Bullish Signals
Trades at modest single-digit undervaluation vs. GF Value.
Global oral care franchise delivers resilient cash flows.
Risk Factors
Removed from S&P 100, triggering mechanical selling.
P/E ratio of 35.23x trades at a premium.
Bullish Signals
Colgate-Palmolive trades at a modest single-digit percentage undervaluation relative to its proprietary GF Value estimate despite trading above its historical P/E median.
The company's global oral care franchise built around the Colgate brand provides resilient cash flows due to high household penetration and repeat purchase behavior.
Risk Factors
S&P Dow Jones Indices confirmed Colgate-Palmolive will be removed from the S&P 100 index, likely triggering mechanical selling by passive index and ETF products.
The company's price-to-earnings ratio of 35.23 times trailing twelve-month earnings indicates it is trading at a premium versus its own historical earnings multiple.
Colgate-Palmolive (CL) is set to report second-quarter 2026 earnings on Friday, following a first quarter where the company beat EPS estimates for four consecutive quarters. However, Q1 results revealed a divergence in performance: while net sales grew 8.4% driven by a significant foreign exchange tailwind, organic sales rose only 2.9%. Gross margins slipped 20 basis points to 60%, and North America saw sales decline sharply despite strong growth in Latin America, Europe, and Asia Pacific.
Management has flagged approximately $300 million in additional raw material and logistics costs for 2026, with oil byproduct spending up over 20% year-over-year. Consequently, Colgate cut its full-year gross margin guidance, expecting margins to fall on both reported and adjusted bases, though it maintained sales and EPS guidance of 2-6% and 1-4% respectively. The company faces rising input costs due to Middle East tensions pushing oil prices near $90, which threatens the assumptions behind current financial projections.
Key strengths include a robust dividend history with a yield near 2.3%, a dominant 41% global toothpaste market share providing a defensive moat, and resilient pet nutrition business where Hill's continues to grow. Conversely, risks persist in North America due to intensified competition, consumer trade-downs to private labels, and tariff costs that have forced volume sacrifices. The stock trades at roughly 24.5 times forward earnings, leaving little margin for error given the threat of rising input costs and potential FX headwinds if the dollar strengthens.
📈 CL beat EPS estimates for four consecutive quarters averaging 3%.
📉 Organic sales grew only 2.9% excluding currency and acquisitions.
💰 Gross margins slipped 20 basis points to 60% in Q1.
⚠️ Management flagged $300M additional raw material and logistics costs for 2026.
🛢️ Oil byproduct spending is running over 20% higher year over year.
📈 Colgate-Palmolive (CL) beat EPS estimates for four consecutive quarters with an average beat of about 3%.
📉 Q1 net sales grew 8.4%, but organic sales excluding currency and acquisitions only increased by 2.9%.
💰 Gross margins slipped 20 basis points to 60% in the first quarter.
🌍 Strong growth came from outside North America, with Latin America, Europe, and Asia Pacific posting solid numbers.
📉 North American sales fell sharply, causing operating profit to drop significantly in the region.
⚠️ Management flagged roughly $300 million in additional raw material and logistics costs for 2026.
🛢️ Spending on oil byproducts, including resins and fats, is running more than 20% higher year over year.
📉 Logistics costs are up nearly 10% across both ocean and land freight operations.
📉 Colgate cut its full-year gross margin guidance as a result of rising input costs.
💰 The company kept its full-year sales and EPS guidance intact despite the margin cut.
🌍 Emerging markets are working well, with Asia Pacific and Latin America delivering strong growth.
🐾 Hill's pet nutrition business is holding up well as consumers prioritize pet spending over their own.
💵 The dividend remains untouchable with a quarterly payout of $0.53 per share and a yield near 2.3%.
🦷 Colgate holds a 41% global toothpaste market share, providing a genuine moat in the category.
⚠️ Rising oil prices undercut current guidance assumptions, potentially leading to further margin cuts.
Bullish Signals
Beat EPS estimates four quarters with ~3% average beat.
Risk Factors
Gross margins slipped 20 bps to 60% in Q1.
Bullish Signals
Colgate-Palmolive has beaten EPS estimates in each of the last four quarters with an average beat of about 3%.
Emerging markets are driving growth, with Asia Pacific and Latin America posting strong numbers due to pricing actions and improving volumes.
The pet nutrition business is resilient, with Hill's continuing to grow as consumers prioritize pet spending over their own.
Colgate maintains a robust dividend history, having raised its payout for decades with a current yield near 2.3%.
The company holds a dominant 41% global toothpaste market share, providing a defensive moat in a recession-resistant category.
Risk Factors
Gross margins slipped 20 basis points to 60% in the first quarter.
North American sales fell and operating profit dropped sharply due to intensified competition and consumer trade-downs.
Management flagged roughly $300 million in additional raw material and logistics costs for 2026, with oil byproduct spending up over 20% year-over-year.
Colgate cut its full-year gross margin guidance as a result of rising input costs, expecting margins to fall on both reported and adjusted bases.
Rising oil prices near $90 due to Middle East tensions threaten the assumptions behind current financial guidance.
The FX tailwind can reverse quickly if the dollar strengthens, which would cause reported growth to drop fast from its organic base.
North America faces structural challenges including tariff costs that hit without relief and a need for brand interventions to fix volume issues.
Colgate-Palmolive (NYSE:CL) recently reported quarterly earnings that exceeded analyst expectations, with EPS of $0.99 beating the consensus estimate of $0.95. Revenue reached $5.36 billion, representing a 4.9% year-over-year increase. The company maintains a consensus recommendation of 'Moderate Buy' from nineteen brokerages, with twelve issuing buy ratings and seven holding steady.
Wall Street analysts have recently adjusted their price targets for the stock. Piper Sandler lifted its target to $96.00 with an 'overweight' rating, while Deutsche Bank set a target of $101.00. Conversely, JPMorgan Chase lowered its target from $104.00 to $103.00, and TD Cowen raised its target to $90.00 but maintained a 'hold' rating. The average 12-month price target among covering analysts is approximately $99.
The company offers an income-focused profile with a quarterly dividend of $0.53 per share, equating to a $2.12 annualized payout and a 2.4% yield. However, the payout ratio is noted as relatively high at 84.13%. Recent insider activity includes significant sales by COO Panagiotis Tsourapas and Director John T. Cahill, with over $16 million in shares sold by insiders in the last 90 days.
Institutional ownership remains strong at 80.41%, driven by major inflows from entities like California State Teachers Retirement System and Bank of New York Mellon Corp. The stock currently trades around $89.89, with a market capitalization of $71.66 billion and a PE ratio of 35.67.
📈 EPS beat consensus at $0.99 vs $0.95 estimate.
💰 Revenue grew 4.9% YoY to $5.36 billion.
🏦 Consensus rating is Moderate Buy with $99 target.
⚠️ High dividend payout ratio of 84.13%.
📉 Executives sold shares totaling over $1.3 million.
📈 Colgate-Palmolive reported quarterly EPS of $0.99, beating the consensus estimate of $0.95.
💰 Revenue grew 4.9% year-over-year to reach $5.36 billion in the latest quarter.
🏦 The stock holds a consensus 'Moderate Buy' rating from nineteen brokerages with an average 12-month price target of $99.
📉 Piper Sandler raised its price target to $96.00 and upgraded the rating to 'overweight'.
📈 Deutsche Bank restated a 'buy' rating with a higher price target of $101.00.
📉 JPMorgan Chase lowered its price target from $104.00 to $103.00 while maintaining an 'overweight' rating.
💸 The company pays a quarterly dividend of $0.53, resulting in a 2.4% annualized yield.
⚠️ The dividend payout ratio is relatively high at 84.13%, indicating a significant portion of earnings are distributed.
📉 COO Panagiotis Tsourapas sold 10,000 shares for $920,500 in a recent transaction.
📉 Director John T. Cahill sold 4,170 shares for $389,352.90 following the quarter's close.
🏛️ Institutional ownership stands at 80.41%, with major inflows from California State Teachers Retirement System.
📊 The stock has a market cap of $71.66 billion and a PE ratio of 35.67.
Bullish Signals
EPS beat estimates at $0.99 vs $0.95 consensus.
Revenue grew 4.9% YoY to $5.36 billion.
Nineteen brokerages maintain a 'Moderate Buy' rating.
Piper Sandler raised target to $96 with 'overweight'.
Deutsche Bank set $101 price target on 'buy'.
Risk Factors
Dividend payout ratio is high at 84.13%.
COO sold 10,000 shares for $920,500.
Director Cahill sold 4,170 shares for $389,352.
Bullish Signals
Colgate-Palmolive reported quarterly earnings of $0.99 per share, exceeding the consensus estimate of $0.95.
Revenue increased by 4.9% year-over-year to reach $5.36 billion in the most recent quarter.
The company maintains a consensus 'Moderate Buy' recommendation from nineteen brokerages covering the stock.
Piper Sandler lifted its price target to $96.00 and assigned an 'overweight' rating to the shares.
Deutsche Bank restated a 'buy' rating and set a price target of $101.00 on the company's stock.
The firm offers a 2.4% dividend yield with an annualized payout of $2.12 per share.
Risk Factors
The company's dividend payout ratio is relatively high at 84.13%, suggesting limited room for dividend growth.
COO Panagiotis Tsourapas sold 10,000 shares of the stock in a transaction worth $920,500.
Director John T. Cahill sold 4,170 shares of the firm's stock for a total value of $389,352.90.
JPMorgan Chase dropped its price target on Colgate-Palmolive from $104.00 to $103.00.
Colgate-Palmolive (NYSE:CL) recently reported quarterly earnings that exceeded analyst expectations, with EPS of $0.99 beating the consensus estimate of $0.95. Revenue reached $5.36 billion, representing a 4.9% year-over-year increase. The company maintains a consensus recommendation of 'Moderate Buy' from nineteen brokerages, with twelve issuing buy ratings and seven holding steady.
Wall Street analysts have set an average 12-month price target of $99, compared to the stock's opening price of $89.89. Recent analyst actions include Piper Sandler lifting its target price to $96 with an 'overweight' rating, Deutsche Bank restating a 'buy' with a $101 target, and TD Cowen raising its target to $90. Conversely, JPMorgan Chase slightly lowered its target from $104 to $103 while maintaining an 'overweight' stance.
The company offers a quarterly dividend of $0.53 per share, equating to a 2.4% annualized yield, though the payout ratio is noted as high at 84.13%. Financial metrics show a market capitalization of $71.66 billion, a PE ratio of 35.67, and a return on equity of 464.63%. However, insider selling activity was observed in late August, with COO Panagiotis Tsourapas and Director John T. Cahill reducing their shareholdings.
📈 EPS beat consensus at $0.99 vs $0.95 estimate.
💰 Revenue grew 4.9% YoY to $5.36 billion.
🏦 Consensus rating is Moderate Buy from 19 brokerages.
🎯 Average 12-month price target is $99 with upside.
⚠️ High dividend payout ratio of 84.13% noted.
📈 Colgate-Palmolive reported quarterly EPS of $0.99, beating the consensus estimate of $0.95.
💰 Revenue grew 4.9% year-over-year to reach $5.36 billion in the latest quarter.
🏦 The stock holds a consensus 'Moderate Buy' rating from nineteen brokerages covering the company.
🎯 Analysts have set an average 12-month price target of $99, implying upside from the current trading level.
💵 The company pays a quarterly dividend of $0.53, resulting in a 2.4% annualized yield for shareholders.
⚠️ The dividend payout ratio is relatively high at 84.13%, indicating a significant portion of earnings is distributed.
📉 Piper Sandler lifted its price target to $96 and upgraded the rating to 'overweight' in July.
📉 Deutsche Bank restated a 'buy' rating with a $101 price target in early August.
📉 JPMorgan Chase lowered its price target from $104 to $103 while maintaining an 'overweight' rating.
📉 TD Cowen raised its price target to $90 but kept the rating as 'hold' in August.
📉 Insider selling occurred recently, with COO Panagiotis Tsourapas and Director John T. Cahill reducing their stakes.
🏛️ Institutional ownership remains strong at 80.41%, with significant holdings from California State Teachers Retirement System.
Bullish Signals
EPS beat estimates at $0.99 vs $0.95 consensus.
Revenue grew 4.9% YoY to $5.36 billion.
Nineteen brokerages rate stock as 'Moderate Buy'.
Average 12-month price target is $99.
Strong institutional ownership stands at 80.41%.
Risk Factors
Dividend payout ratio high at 84.13%, limiting flexibility.
24/7 Wall St. predicts Colgate-Palmolive (NYSE:CL) shares could jump 20% this year, setting a price target of $103.17 with a buy rating and 90% confidence. The stock has already gained 12.04% year-to-date as investors favor its low beta and defensive characteristics amidst macroeconomic uncertainty. With shares trading at $87.44, the analysis suggests significant upside potential driven by accelerating organic sales growth and a robust dividend history.
The company recently reported strong Q1 2026 earnings, beating adjusted EPS expectations of $0.97 versus consensus and extending a four-quarter beat streak. Revenue grew 8.4% year-over-year to $5.324 billion, with standout performance in Latin America (up 14.8%) and Europe (up 11.9%), while free cash flow surged 27.94% to $609 million. The dividend was increased to $0.53 per quarter, marking the 63rd consecutive annual increase.
The bullish case relies on three main pillars: accelerating organic sales growth in emerging markets, a restructuring program targeting $200-$300 million in annual pretax savings, and a resilient balance sheet. However, risks include ongoing tariff pressures that have forced management to revise gross margin guidance downward and a recent $919 million goodwill impairment related to the Filorga skin health business due to weakness in China.
Analysts note that while the trailing P/E of 34 appears high, it is distorted by the one-time Filorga charge, making the forward P/E of 23 more relevant. The model projects a bear-case floor of $92.10, highlighting the downside protection provided by the stock's low volatility and consistent dividend payments. Key risks to monitor include further tariff escalation and volume deterioration in North America.
📈 Analysts target $103.17 price with 20% predicted jump this year.
Colgate-Palmolive (India) Ltd reported its strongest quarterly performance in eight quarters for Q1FY27, with total operating revenues surging 11.8% year-on-year to ₹483 crore in Ebitda. This growth was driven by high single-digit volume expansion and stellar sales of premium toothpaste, outperforming rival Hindustan Unilever in the oral care category.
Despite the robust revenue beat, investor sentiment remains cautious as shares dipped 2% post-results. Analysts attribute this to a favorable base effect from last year's decline and slower Ebitda growth of 6.7%, which saw margins contract by 144 basis points to 30.1% due to a sharp 34% jump in advertising expenses to ₹252 crore.
Looking ahead, the company plans to manage margin volatility through cost-saving initiatives and calibrated pricing actions amidst geopolitical uncertainties. While input cost inflation may slightly moderate gross margins in Q2, analysts expect mid-single-digit pricing growth to ease pressure and drive double-digit Ebitda expansion from the next quarter.
📈 Revenue grew 11.8% YoY, best in eight quarters.
🦷 Premium toothpaste drove volume expansion and stellar results.
💰 Gross margin expanded to 70% via cost savings.
📉 Ebitda margins contracted 144 bps due to ad spend surge.
🚀 New launches fuel premiumization trend for future growth.
📈 Colgate-Palmolive (India) Ltd achieved an 11.8% year-on-year revenue growth in Q1FY27, marking its best performance in eight quarters.
🦷 Premium toothpaste delivered stellar results, supported by sustained growth across the core portfolio and high single-digit volume expansion.
💰 Gross margin expanded by 104 basis points to 70% due to successful cost-saving initiatives despite rising input costs.
📉 Ebitda grew at a slower pace of 6.7% YoY, with margins contracting 144 bps to 30.1% primarily driven by a 34% surge in advertising spend.
📊 The stock is down 2% since results were declared, reflecting investor caution regarding the favorable base effect from Q1FY26's revenue decline.
🚀 New product launches like MaxFresh Berry Blast and Colgate Total Active Prevention Foaming Clean Toothbrush are driving the premiumization trend.
🔮 Nomura Research forecasts that mid-single-digit pricing growth will help drive double-digit Ebitda growth starting in Q2.
📉 Input cost inflation is expected to cause a slight moderation in gross margins during the upcoming quarter.
🏢 Jefferies analysts note that valuations at 38x P/E are at the lower end of the sector, offering potential upside if growth momentum sustains.
Bullish Signals
Revenues grew 11.8% YoY in Q1FY27.
Gross margin expanded 104 bps to 70%.
Premium toothpaste and core portfolio drove growth.
New launches successfully driving premiumization trend.
Analysts expect double-digit Ebitda growth from Q2.
Risk Factors
Shares down 2% despite revenue beat.
Ebitda growth slowed to 6.7%; margins contracted 144 bps.
Colgate-Palmolive India reported strong first-quarter financial results, with revenue growing 11.8% year-on-year to ₹1,603 crore, driven by high-single-digit volume growth in the toothpaste segment which exceeded market expectations.
While top-line performance was robust, profitability faced headwinds from a significant increase in advertising expenditures. Ad spends jumped 33% to ₹252 crore, raising the ad spend-to-sales ratio from 13.1% to 15.7%, which compressed EBITDA margins to 30.1% from 31.6%.
Despite margin pressure, net profit grew 6.9% to ₹343 crore, aligning with analyst estimates, while gross margins expanded by 110 basis points to 69.7% due to cost savings and financial discipline. Management indicated that these strong margins are being leveraged for brand building and premiumization.
The stock reacted positively to the earnings announcement, gaining up to 2.5% intraday and trading 1.2% higher at ₹2,164.3. Shares have risen over 8% in the last month as investors appear to view the volume growth and margin expansion strategy favorably despite the temporary hit from ad spending.
📈 Revenue grew 11.8% to ₹1,603 crore driven by toothpaste volume.
💰 EBITDA rose 6.6% to ₹482 crore meeting market expectations.
📉 Ad spend surged 33% to ₹252 crore raising sales ratio.
📊 Gross margins expanded 110 bps to 69.7% via cost savings.
💹 Net profit increased 6.9% to ₹343 crore with core growth.
📈 Revenue grew 11.8% year-on-year to ₹1,603 crore, driven by high-single-digit volume growth in the toothpaste segment.
💰 EBITDA increased 6.6% to ₹482 crore, meeting street expectations despite margin compression.
📉 Ad spends surged 33% to ₹252 crore, increasing the ad spend-to-sales ratio from 13.1% to 15.7%.
📊 Gross margins expanded by 110 basis points to 69.7%, aided by cost savings and financial discipline.
💹 Net profit rose 6.9% to ₹343 crore, with core profitability growing 11% excluding one-offs.
🚀 Stock price gained up to 2.5% intraday, trading at ₹2,164.3 after the earnings release.
📈 Shares are up over 8% in the last month following the positive market reaction to Q1 results.
🗣️ MD & CEO Prabha Narasimhan stated that strong margins are being used for brand building and category premiumisation.
🔬 Management expects sustainable future growth fueled by science-backed products and continued advertising investment.
📅 Results were released on July 29, 2026, with revenue beating the CNBC-TV18 poll estimate of ₹1,577 crore.
Bullish Signals
Revenue grew 11.8% YoY to ₹1,603 crore.
Gross margins expanded 110 bps to 69.7%.
Net profit rose 6.9% to ₹343 crore.
Shares up over 8% in the last month.
Risk Factors
EBITDA margins narrowed to 30.1% due to 33% ad spend rise.
Ad spend-to-sales ratio increased to 15.7%, impacting profitability.
Bullish Signals
Revenue grew 11.8% year-on-year to ₹1,603 crore, significantly outperforming the analyst consensus estimate of ₹1,577 crore.
Toothpaste volume growth was high-single-digit, exceeding street expectations of mid-single-digit growth and driving top-line expansion.
Gross margins expanded by 110 basis points to 69.7%, demonstrating effective cost management and financial discipline despite inflationary pressures.
Net profit grew 6.9% to ₹343 crore, while core profitability excluding one-offs surged 11% year-on-year.
Shares rallied up to 2.5% intraday and are up over 8% in the last month, indicating strong investor confidence in the results.
Management is successfully leveraging improved margins for strategic investments in brand building and category premiumisation.
Risk Factors
EBITDA margins narrowed to 30.1% from 31.6% due to a sharp 33% increase in advertising spends to ₹252 crore.
The ad spend-to-sales ratio increased to 15.7% from 13.1%, indicating higher marketing intensity that temporarily impacted bottom-line profitability.
Aristotle Atlantic Partners LLC acquired a new stake of 12,000 shares in Colgate-Palmolive Company (NYSE:CL) valued at approximately $1.02 million during the first quarter. Several other institutional investors, including Kemnay Advisory Services Inc., CBIZ Investment Advisory Services LLC, TD Capital Management LLC, Triumph Capital Management, and Jessup Wealth Management Inc., also increased or initiated positions in the fourth quarter, collectively raising hedge fund ownership to 80.41% of the company's stock.
Wall Street analysts have issued mixed ratings on Colgate-Palmolive, with Goldman Sachs, Deutsche Bank, and Citigroup maintaining or upgrading 'buy' ratings, while Wall Street Zen downgraded the stock to a 'hold.' The consensus price target stands at $97.82, with an average rating of 'Moderate Buy.' Recent financial data shows the stock trading around $90.74, supported by strong earnings performance and a solid balance sheet.
Colgate-Palmolive reported quarterly earnings of $0.97 per share, beating analyst estimates of $0.94, with revenue reaching $5.32 billion against a consensus of $5.22 billion. The company achieved a net margin of 10.04% and a return on equity of 386.76%, with revenue growing 8.4% year-over-year. Analysts forecast an annual EPS of 3.81 for the current year, reflecting continued operational strength in its core consumer products portfolio.
The company declared a quarterly dividend of $0.53 per share, payable on August 14th to shareholders of record as of July 20th, representing an annualized yield of 2.3%. With a market capitalization of $72.61 billion and a P/E ratio of 35.31, Colgate-Palmolive continues to demonstrate resilient financial health across its oral care, personal care, home care, and pet nutrition segments.
📈 Aristotle Atlantic Partners bought 12,000 shares worth $1.02 million in Q1.
🏦 Hedge funds now own 80.41% of Colgate-Palmolive's outstanding stock.
💰 Stock trades at $97.82 consensus target with a 'Moderate Buy' rating.
💵 Quarterly earnings beat estimates, reaching $0.97 per share and $5.32B revenue.
🚀 Revenue grew 8.4% year-over-year driven by strong consumer demand.
📈 Aristotle Atlantic Partners LLC purchased 12,000 shares of Colgate-Palmolive (NYSE:CL) worth approximately $1.02 million in the first quarter.
📊 Multiple institutional investors including Kemnay Advisory Services Inc., CBIZ Investment Advisory Services LLC, TD Capital Management LLC, Triumph Capital Management, and Jessup Wealth Management Inc. increased their stakes in the fourth quarter.
🏦 Hedge funds and other institutional investors now own 80.41% of Colgate-Palmolive's outstanding stock.
📉 Wall Street Zen downgraded Colgate-Palmolive from a 'buy' to a 'hold' rating on March 29th.
🔍 Goldman Sachs, Deutsche Bank, and Citigroup maintained or upgraded their 'buy' ratings with price targets ranging from $85.00 to $110.00.
💰 The stock currently has an average analyst rating of 'Moderate Buy' with a consensus price target of $97.82.
📈 Shares of CL opened at $90.74, trading above its 50-day moving average of $90.77 and below its 200-day moving average of $88.96.
💵 Colgate-Palmolive reported quarterly earnings of $0.97 per share, beating analyst estimates of $0.94 by $0.03.
📈 Revenue reached $5.32 billion during the quarter, surpassing consensus estimates of $5.22 billion.
📊 The company achieved a net margin of 10.04% and a return on equity of 386.76% for the quarter.
🚀 Revenue grew 8.4% compared to the same quarter last year, indicating strong consumer demand.
💸 Analysts forecast an annual EPS of 3.81 for the current year based on current performance trends.
💰 The company declared a quarterly dividend of $0.53 per share, payable on August 14th to shareholders of record as of July 20th.
📈 The dividend represents an annualized yield of 2.3% with a payout ratio of 82.49%.
🏢 Colgate-Palmolive operates in oral care, personal care, home care, and pet nutrition segments globally.
📉 The stock has a market cap of $72.61 billion and a P/E ratio of 35.31.
📊 The company's debt-to-equity ratio is 16.33 with a current ratio of 1.02 and quick ratio of 0.67.
📈 The stock has a beta of 0.33, indicating lower volatility compared to the broader market.
📉 The 1-year low for CL is $74.54 and the 1-year high is $99.33.
🔍 Twelve investment analysts have rated the stock with a 'Buy' rating while seven have assigned a 'Hold' rating.
Bullish Signals
New stake: 12,000 shares valued at $1.02 million.
Institutional ownership reached 80.41% of outstanding stock.
Analysts maintain 'buy' ratings with targets from $85 to $110.
Consensus price target is $97.82 with a 'Moderate Buy' rating.
Earnings beat estimates at $0.97 per share.
Revenue reached $5.32 billion, beating the $5.22 estimate.
Quarterly dividend of $0.53 with 2.3% annualized yield.
Bullish Signals
Aristotle Atlantic Partners LLC acquired a new stake of 12,000 shares valued at approximately $1.02 million in the first quarter.
Multiple institutional investors including Kemnay Advisory Services Inc., CBIZ Investment Advisory Services LLC, TD Capital Management LLC, Triumph Capital Management, and Jessup Wealth Management Inc. increased their stakes in the fourth quarter.
Hedge funds and other institutional investors now own 80.41% of Colgate-Palmolive's outstanding stock.
Goldman Sachs, Deutsche Bank, and Citigroup maintained or upgraded their 'buy' ratings with price targets ranging from $85.00 to $110.00.
The stock currently has an average analyst rating of 'Moderate Buy' with a consensus price target of $97.82.
Shares of CL opened at $90.74, trading above its 50-day moving average of $90.77 and below its 200-day moving average of $88.96.
Colgate-Palmolive reported quarterly earnings of $0.97 per share, beating analyst estimates of $0.94 by $0.03.
Revenue reached $5.32 billion during the quarter, surpassing consensus estimates of $5.22 billion.
The company achieved a net margin of 10.04% and a return on equity of 386.76% for the quarter.
Revenue grew 8.4% compared to the same quarter last year, indicating strong consumer demand.
Analysts forecast an annual EPS of 3.81 for the current year based on current performance trends.
The company declared a quarterly dividend of $0.53 per share, payable on August 14th to shareholders of record as of July 20th.
The dividend represents an annualized yield of 2.3% with a payout ratio of 82.49%.
Colgate-Palmolive (NYSE:CL) is scheduled to release its Q2 2026 earnings results before the market opens on Friday, July 31st. Analysts currently project earnings per share of $0.9470 and revenue of $5.3563 billion for the quarter. The company previously reported strong results in May, beating consensus estimates with EPS of $0.97 versus an expected $0.94 and revenue of $5.32 billion against a forecast of $5.22 billion.
The stock currently trades at $89.98 with a market capitalization of $72.00 billion. Key valuation metrics include a price-to-earnings ratio of 35.01, a PEG ratio of 4.83, and a beta of 0.33. The company maintains a net margin of 10.04% and a return on equity of 386.76%, with revenue growing 8.4% year-over-year. Analysts have set an average consensus target price of $97.82 based on data from MarketBeat.
Recent analyst activity shows mixed but generally positive sentiment, with UBS Group raising its target price to $106.00 and Deutsche Bank maintaining a buy rating at $99.00, though Wall Street Zen recently downgraded the stock to a hold. Institutional ownership remains robust at 80.41%, with significant stake increases from major funds including Amundi, Two Sigma Investments LP, and the Canada Pension Plan Investment Board during recent quarters.
📅 Colgate-Palmolive releases Q2 2026 earnings Friday, July 31st.
💰 Analysts expect $0.95 EPS and $5.36 billion revenue.
🏢 Market cap is $72 billion with a P/E of 35.01.
🎯 Consensus target price is $97.82 with Moderate Buy rating.
🚀 Institutional ownership reached 80.41% as major funds increased stakes.
📅 Colgate-Palmolive is set to release Q2 2026 earnings before market open on Friday, July 31st.
💰 Analysts expect EPS of $0.9470 and revenue of $5.3563 billion for the upcoming quarter.
📈 The company previously beat estimates in May with $0.97 EPS and $5.32 billion in revenue.
🏢 Market cap stands at $72.00 billion with a P/E ratio of 35.01 and a beta of 0.33.
📊 Revenue grew 8.4% year-over-year, reaching $5.32 billion in the last reported quarter.
🎯 The consensus analyst target price is $97.82 with an average rating of Moderate Buy.
🔼 UBS Group raised its price target to $106.00 and reaffirmed a buy rating recently.
📉 Wall Street Zen lowered the rating from buy to hold in late March.
🏦 Institutional ownership is high at 80.41% with major funds increasing stakes significantly.
🚀 Amundi grew its stake by 41.6%, while Two Sigma raised holdings by 360.9%.
Bullish Signals
Beat EPS estimates at $0.97 vs $0.94 consensus.
Revenue exceeded forecast at $5.32 billion vs $5.22B.
UBS raised price target to $106 with buy rating.
Deutsche Bank restated buy rating with $99 price target.
Amundi increased stake 41.6% to own 6.2M shares.
Two Sigma raised position 360.9% to hold 2.1M shares.
Canada Pension Plan boosted holdings by 392.8% in Q2.
Revenue grew 8.4% year-over-year in last reported quarter.
Risk Factors
Analysts lowered rating from buy to hold in late March.
High P/E ratio of 35.01 suggests valuation concerns.
Bullish Signals
The company recently beat earnings estimates with $0.97 EPS compared to a consensus of $0.94.
Revenue exceeded expectations at $5.32 billion versus the forecasted $5.22 billion.
UBS Group increased its price target to $106.00 and maintained a buy rating on Thursday, July 16th.
Deutsche Bank Aktiengesellschaft restated a buy rating with a $99.00 price target in May.
Amundi significantly increased its stake by 41.6% to own over 6.2 million shares valued at nearly $488 million.
Two Sigma Investments LP raised its position by 360.9%, now holding over 2.1 million shares worth approximately $170 million.
The Canada Pension Plan Investment Board boosted its holdings by 392.8% in the second quarter.
Revenue demonstrated solid growth of 8.4% on a year-over-year basis during the last reported quarter.
Risk Factors
Wall Street Zen lowered its rating from buy to hold in late March, indicating some caution among analysts.
The stock trades at a high P/E ratio of 35.01 and a PEG ratio of 4.83, suggesting potential valuation concerns relative to growth.
UBS Group raised its price target for Colgate-Palmolive (NYSE:CL) to $106.00 from $100.00, maintaining a buy rating. This follows a series of analyst actions including Piper Sandler lifting its target to $96.00 with an overweight rating and Goldman Sachs restating a buy. Conversely, Bank of America lowered its target to $102.00, while Sanford C. Bernstein initiated coverage with a market perform rating at $96.00. The consensus remains a Moderate Buy with a price target of $97.41 based on twelve buy and seven hold ratings.
Colgate-Palmolive reported strong financial results for the quarter ending May 1st, posting $0.97 in earnings per share against a consensus estimate of $0.94. Revenue reached $5.32 billion, exceeding analyst expectations of $5.22 billion and representing an 8.4% year-over-year increase. The company demonstrated robust profitability with a return on equity of 386.76% and a net margin of 10.04%, while the prior year quarter saw earnings of $0.91 per share.
The company announced a quarterly dividend to be paid on August 14th for shareholders of record on July 20th, offering $0.53 per share. This translates to an annualized dividend of $2.12 with a yield of 2.3% and a payout ratio of 82.49%. Institutional investors have also increased their stakes, with HighPoint Advisor Group LLC raising its position by 0.7% and Clear Harbor Asset Management LLC lifting holdings by 2.6% in the fourth quarter.
📈 UBS raised price target to $106.00, maintaining buy rating.
📊 Q2 EPS beat estimates at $0.97 versus $0.94 consensus.
💰 Revenue grew 8.4% YoY to $5.32 billion.
📉 Bank of America lowered target to $102.00, still buy.
💵 Dividend of $0.53/share pays August 14th (ex-date July 20).
📈 UBS Group raised Colgate-Palmolive's price target to $106.00 from $100.00 while maintaining a buy rating.
📊 The company beat Q2 earnings estimates with $0.97 EPS versus the consensus of $0.94.
💰 Revenue grew 8.4% year-over-year to reach $5.32 billion, surpassing analyst expectations of $5.22 billion.
📉 Bank of America lowered its price target to $102.00 despite maintaining a buy rating on the stock.
💵 A quarterly dividend of $0.53 per share will be paid on August 14th with an ex-dividend date of July 20th.
🏦 HighPoint Advisor Group LLC increased its stake by 0.7% to own 15,877 shares valued at $1.255 million.
📈 Clear Harbor Asset Management LLC boosted its holdings by 2.6% in the fourth quarter.
🔍 The stock holds a consensus rating of Moderate Buy with an average price target of $97.41 from twelve analysts.
🏭 Colgate-Palmolive operates globally in oral care, personal care, home care, and pet nutrition categories.
📉 The company reported a return on equity of 386.76% and a net margin of 10.04% for the quarter.
Bullish Signals
UBS raised price target to $106.00.
Earnings beat estimates by $0.03 per share.
Revenue grew 8.4% YoY to $5.32 billion.
Consensus is Moderate Buy with twelve buy ratings.
Dividend yield stands at 2.3% with $2.12 annual payout.
Risk Factors
Bank of America cut target from $105.00 to $102.00.
Bernstein initiates neutral with $96.00 price target.
Bullish Signals
UBS Group raised its price target to $106.00, signaling confidence in the stock's valuation.
The company beat quarterly earnings estimates by $0.03 per share, demonstrating operational strength.
Revenue increased by 8.4% year-over-year to $5.32 billion, exceeding analyst forecasts of $5.22 billion.
Analyst consensus remains a Moderate Buy with twelve buy ratings compared to seven hold ratings.
The company maintains a healthy dividend yield of 2.3% with an annualized payout of $2.12 per share.
Institutional investors like HighPoint Advisor Group LLC and Clear Harbor Asset Management LLC increased their positions.
Risk Factors
Bank of America decreased its price target from $105.00 to $102.00, indicating some caution on valuation.
Sanford C. Bernstein initiated coverage with a neutral market perform rating and a lower $96.00 price target.
UBS Group raised its price target on Colgate-Palmolive (NYSE:CL) from $100.00 to $106.00, citing a potential upside of 14.17% from the previous close, while maintaining a 'buy' rating. This follows a series of analyst actions including Wells Fargo increasing its target to $95.00 with an 'equal weight' rating and Citigroup raising its target to $110.00 with a 'buy' rating. Conversely, Wall Street Zen downgraded the stock from 'buy' to 'hold', resulting in a consensus average target price of $97.41 based on ratings from twelve buy analysts and seven hold analysts.
The company recently reported quarterly earnings for the quarter ended May 1st, beating analyst expectations with EPS of $0.97 versus a consensus of $0.94. Revenue reached $5.32 billion, surpassing the expected $5.22 billion, representing an 8.4% year-over-year increase. Key financial metrics included a return on equity of 386.76% and a net margin of 10.04%, with analysts forecasting an average EPS of $3.81 for the current year.
Institutional ownership remains strong at 80.41%, with several major investors increasing their stakes in the fourth quarter. HighPoint Advisor Group LLC grew its holdings by 0.7% to own 15,877 shares valued at $1.255 million, while Clear Harbor Asset Management LLC increased its position by 2.6% to hold 4,503 shares worth $356,000. Other active investors include Moneta Group Investment Advisors LLC and Cooper Financial Group, which boosted their positions by 0.7% and 4.0% respectively.
📈 UBS raised price target to $106, projecting 14.17% upside.
📊 EPS beat estimates at $0.97; revenue hit $5.32 billion.
📈 Year-over-year revenue growth reached 8.4% for the quarter.
🏦 Institutional ownership remains high at 80.41%.
📉 Wall Street Zen downgraded stock to 'hold' with $97.41 target.
📈 UBS Group raised its price target on Colgate-Palmolive from $100.00 to $106.00, projecting a 14.17% upside potential.
📊 The company reported quarterly EPS of $0.97, beating the consensus estimate of $0.94 by $0.03.
💰 Revenue for the quarter reached $5.32 billion, exceeding analyst expectations of $5.22 billion.
📈 Year-over-year revenue growth was recorded at 8.4% during the reported quarter.
🏦 Return on equity stood at 386.76% with a net margin of 10.04% for the period.
👔 HighPoint Advisor Group LLC increased its holdings by 0.7% to own 15,877 shares valued at $1.255 million.
📉 Clear Harbor Asset Management LLC lifted its position by 2.6% to hold 4,503 shares worth $356,000.
🏛️ Institutional and hedge fund ownership of the stock remains high at 80.41%.
📉 Wall Street Zen downgraded the stock from 'buy' to 'hold' in a recent research report.
🎯 The average analyst price target across twelve buy and seven hold ratings is $97.41.
Bullish Signals
UBS raised target to $106.00, showing 14.17% upside.
Colgate-Palmolive beat EPS at $0.97 vs $0.94 consensus.
Revenue hit $5.32 billion, beating the $5.22 forecast.
Revenue grew 8.4% year-over-year, signaling strong business growth.
Citigroup raised target to $110.00 with a buy rating.
Bullish Signals
UBS Group increased its price target by $6.00 to $106.00, indicating a bullish outlook with 14.17% upside potential.
Colgate-Palmolive beat quarterly earnings expectations with EPS of $0.97 compared to the consensus of $0.94.
Revenue of $5.32 billion exceeded analyst forecasts of $5.22 billion, demonstrating strong top-line performance.
The company achieved an 8.4% year-over-year revenue increase, signaling robust business growth.
HighPoint Advisor Group LLC and Clear Harbor Asset Management LLC both increased their holdings in the fourth quarter.
Institutional ownership stands at 80.41%, reflecting continued confidence from major investors and hedge funds.
Citigroup raised its price target to $110.00 with a 'buy' rating, adding to the positive analyst sentiment.
Colgate-Palmolive Company (CL) is presented as a high-quality dividend growth stock with a share price of $92.07 as of June 26, 2026. The company operates globally across over 200 countries, deriving 77% of its revenue from oral, personal, and home care segments, while Hill's Pet Nutrition accounts for the remaining 23%. Management under CEO Noel Wallace has executed a 2030 strategic plan that has delivered six consecutive years of organic sales growth and annual revenues exceeding $20 billion.
The article highlights Colgate's robust competitive moat, characterized by dominant global brands, significant pricing power, and an extensive distribution network securing over 40% of the global toothpaste market. Financially, the company demonstrates disciplined capital allocation with high returns on invested capital, annual share repurchases exceeding $1 billion, and a status as a Dividend King with 63 consecutive years of dividend increases. Long-term growth is supported by rising hygiene awareness in emerging markets and the expanding pet nutrition sector.
Despite structural risks including competitive pressures, foreign exchange volatility, input cost inflation, and the maturity of core categories, Colgate maintains a conservative balance sheet and healthy interest coverage. The analysis concludes that these factors support its positioning as a resilient compounder capable of steadily compounding shareholder returns over the long term, distinguishing it from other investment themes like AI stocks mentioned in the text.
📈 Shares trade at $92.07 with forward P/E of 23.87 as of June 26, 2026.
🌍 Operates in 200+ countries with oral, personal, and home care driving 77% of sales.
🦷 Holds over 40% global toothpaste market share supported by strong brand equity.
💰 Dividend King status with 63 years of increases and $1B+ annual buybacks.
⚠️ Faces structural risks including FX volatility, input costs, and core category maturity.
📈 Colgate-Palmolive (CL) shares traded at $92.07 with a trailing P/E of 35.69 and forward P/E of 23.87 as of June 26, 2026.
🌍 The company operates in over 200 countries with a diversified revenue base led by oral, personal, and home care segments contributing 77% of sales.
🦷 Colgate maintains a dominant market position with over 40% share of the global toothpaste market supported by powerful brand equity.
📈 Management under CEO Noel Wallace has achieved six consecutive years of organic sales growth and annual revenue exceeding $20 billion.
💰 The company is a Dividend King with 63 consecutive years of dividend increases and returns over $1 billion annually via share repurchases.
🐾 Hill's Pet Nutrition segment accounts for 23% of sales and is expected to outpace traditional consumer staples due to humanization trends.
💪 Colgate possesses a conservative balance sheet with healthy interest coverage and high returns on invested capital.
⚠️ Structural risks include competitive pressures, foreign exchange volatility, input cost inflation, and the maturity of core categories.
📉 CL stock has depreciated approximately 8.35% since previous bullish coverage in October 2024.
🏦 Hedge fund interest remains stable with 62 portfolios holding CL at the end of Q1 2026, unchanged from the prior quarter.
Bullish Signals
Six consecutive years of organic sales growth with revenue over $20 billion.
Over 40% global toothpaste market share provides strong pricing power.
Dividend King status with 63 consecutive years of dividend increases.
Annual share repurchases exceed $1 billion alongside high returns on invested capital.
Pet nutrition segment positioned for superior growth due to humanization trends.
Risk Factors
Competitive pressures, FX volatility, and input cost inflation risks.
Mature core categories limit high-growth opportunities in oral/home care.
Stock depreciated 8.35% since previous bullish coverage.
Bullish Signals
Colgate has delivered six consecutive years of organic sales growth while maintaining annual revenue above $20 billion.
The company holds a dominant market share of over 40% in the global toothpaste market, providing strong pricing power.
As a Dividend King with 63 consecutive years of dividend increases, Colgate offers exceptional income stability to shareholders.
Disciplined capital allocation is evidenced by high returns on invested capital and annual share repurchases exceeding $1 billion.
The pet nutrition segment is positioned for superior growth compared to traditional consumer staples due to rising pet humanization trends.
Management's 2030 strategic plan successfully integrates digital and physical retail while expanding premium offerings.
Risk Factors
The company faces structural risks from competitive pressures, foreign exchange volatility, and input cost inflation.
Core business categories are maturing, which may limit high-growth opportunities in the traditional oral and home care segments.
CL stock has depreciated by approximately 8.35% since previous bullish coverage, indicating recent market weakness.
Colgate-Palmolive Company (NYSE:CL) recently reported strong quarterly financial results, beating both earnings and revenue estimates. The company posted $0.97 per share in earnings against a consensus of $0.94, driven by sales of $5.32 billion which represented an 8.4% year-over-year increase. This performance highlights the company's resilience and ability to grow revenue despite broader market fluctuations.
Institutional investor activity remains robust for the consumer goods giant. AMI Asset Management Corp significantly increased its stake in Colgate-Palmolive by 17.8% during the first quarter, purchasing an additional 75,262 shares valued at approximately $42.5 million. This move brings AMI's total holding to 498,079 shares, representing about 2.7% of its portfolio and establishing it as the firm's 14th largest position.
The company continues to offer attractive income characteristics with a declared quarterly dividend of $0.53 per share, set for payment on August 14th. This translates to an annualized yield of roughly 2.3% based on current pricing. Analyst sentiment is generally positive, with a consensus price target of $95.88 and a 'Moderate Buy' rating, though individual analyst targets vary from $79 to $100.
Beyond the headline numbers, Colgate-Palmolive maintains a solid balance sheet with a market capitalization of $73.83 billion and a debt-to-equity ratio of 16.33. The stock has shown relative stability compared to the broader market, trading above its 50-day and 200-day moving averages. These fundamentals support its status as a defensive holding within the consumer staples sector.
📈 Colgate-Palmolive beat earnings with $0.97 EPS and $5.32B sales.
💰 Quarterly dividend is $0.53 per share with a 2.3% yield.
🏦 AMI Asset Management increased stake by 17.8% to $42.5M.
📊 Analysts rate stock 'Moderate Buy' with $95.88 price target.
🏛️ Institutional ownership stands at 80.41% indicating strong confidence.
📈 Colgate-Palmolive beat quarterly earnings estimates with $0.97 EPS on $5.32 billion in sales, an 8.4% revenue increase.
🏦 AMI Asset Management Corp increased its stake by 17.8%, buying 75,262 shares worth roughly $42.5 million.
💰 The company declared a quarterly dividend of $0.53 per share with an annualized yield of approximately 2.3%.
📊 Analysts maintain a 'Moderate Buy' consensus rating with a price target of $95.88.
📉 Wells Fargo lowered its price target to $92, while JPMorgan Chase raised its target to $96.
🏛️ Institutional ownership stands at 80.41%, indicating strong confidence from major funds.
📈 The stock trades with a market cap of $73.83 billion and a PEG ratio of 4.85.
🗓️ The next dividend payment is scheduled for August 14th to shareholders of record on July 20th.
Bullish Signals
EPS of $0.97 beat the $0.94 consensus estimate.
Revenue grew 8.4% year-over-year to $5.32 billion.
AMI Asset Management added over $42 million in shares.
Dividend yield is approximately 2.3% with an 82.49% payout ratio.
JPMorgan upgraded price target to $96 with 'overweight' rating.
Risk Factors
Price target cut from $100 to $92 due to cautious outlook.
High PEG ratio of 4.85 suggests overvalued future growth expectations.
Barclays maintains equal weight rating with modest $80 price objective.
Bullish Signals
Colgate-Palmolive exceeded analyst expectations with $0.97 EPS versus the $0.94 consensus estimate.
Revenue grew by 8.4% year-over-year to reach $5.32 billion, demonstrating solid top-line growth.
AMI Asset Management Corp significantly increased its position by 17.8%, adding over $42 million in shares.
The company offers a consistent dividend yield of approximately 2.3% with a payout ratio of 82.49%.
JPMorgan Chase upgraded the price target to $96 and assigned an 'overweight' rating.
Weiss Ratings improved its rating from 'hold (c)' to 'hold (c+)', reflecting positive sentiment.
The stock is trading above both its 50-day ($88.24) and 200-day ($87.23) moving averages.
Risk Factors
Wells Fargo & Company lowered its price target from $100 to $92, citing a more cautious outlook.
The stock carries a high PEG ratio of 4.85, suggesting the market may be pricing in significant future growth.
Barclays maintained an 'equal weight' rating with a modest price objective increase to $80.
Colgate-Palmolive Company (CL) shares have appreciated 16.9% over the past six months, significantly outperforming the Consumer Staples sector and the broader S&P 500. This rally is attributed to strong investor confidence in the company's resilient fundamentals, effective pricing strategies, and a robust innovation pipeline focused on premiumization in oral care and pet nutrition.
The company reported accelerated organic sales growth in the first quarter of 2026, driven by volume trends across all product categories and geographic divisions. Management highlighted broad-based demand, particularly in emerging markets like Asia Pacific and Latin America, alongside strategic investments in digital capabilities, artificial intelligence, and omnichannel demand generation to improve marketing efficiency.
Despite positive momentum, Colgate faces near-term headwinds including elevated costs for raw materials, packaging, and logistics. Consequently, management has lowered its full-year gross margin outlook, anticipating approximately $300 million in additional inflationary costs during 2026 due to higher oil-based inputs and freight expenses. North America remains a weaker operating region due to delayed product launches and competitive promotional environments.
Currently trading at a forward P/E ratio of 23.54, Colgate commands a premium relative to its industry average of 18.42, reflecting confidence in its brand portfolio and pricing power. Analysts view the stock as fairly valued given these near-term margin pressures and elevated valuation, suggesting current investors hold while new investors might wait for a better entry point.
📈 CL shares rose 16.9% in six months, outpacing sector and S&P 500 gains.
🚀 Organic sales growth accelerated in Q1 2026 across all categories and regions.
⚠️ Management lowered full-year gross margin outlook due to $300 million inflationary costs.
💰 Stock trades at forward P/E of 23.54, significantly above industry average of 18.42.
🐾 Hill's Pet Nutrition delivers solid growth despite soft overall pet food market.
📈 CL shares rose 16.9% in six months, outpacing the Consumer Staples sector's 9.5% gain and the S&P 500's 7.3% rise.
🚀 Organic sales growth accelerated in Q1 2026 with strong volume trends across all four product categories and five geographic divisions.
💡 Management is investing in AI, data analytics, and digital capabilities to enhance marketing efficiency and consumer targeting.
🌍 Emerging markets, specifically Asia Pacific and Latin America, delivered meaningful volume acceleration supported by innovation.
🐾 Hill's Pet Nutrition continues to deliver solid organic sales growth despite a soft overall pet food market.
⚠️ Management lowered the full-year gross margin outlook due to approximately $300 million in expected additional inflationary costs.
🛒 North America remains the weakest operating region facing delayed launches, competitive promotions, and tariff-related pressures.
💰 The stock trades at a forward P/E of 23.54, which is significantly higher than the industry average of 18.42.
📉 Analysts rate CL as a Zacks Rank #3 (Hold), suggesting current investors retain positions while new buyers wait for a pullback.
🏭 Higher costs for oil-based inputs like resins, petrochemicals, fats, and oils are driving the margin pressure.
Bullish Signals
CL shares up 16.9% in six months.
Organic sales growth accelerated in Q1 2026.
Investments in AI improve marketing efficiency.
Hill's Pet Nutrition delivers solid organic sales.
Colgate leads in Asia Pacific and Latin America.
Risk Factors
Management lowered full-year gross margin outlook due to $300M inflationary costs.
Elevated raw material, packaging, and logistics costs pressuring profitability.
North America remains weakest region with delayed launches and competition.
Stock trades at premium forward P/E of 23.54 vs industry 18.42.
Tariffs and North American costs may weigh on profitability.
Bullish Signals
CL shares have appreciated 16.9% in six months, demonstrating strong resilience and outperformance against major benchmarks.
Organic sales growth accelerated in Q1 2026, supported by stronger volume trends across all product categories and geographic divisions.
The company is successfully executing an innovation-led strategy with investments in AI and digital capabilities improving marketing efficiency.
Hill's Pet Nutrition remains a key growth engine delivering solid organic sales despite a soft broader market.
Colgate maintains leading market positions and significant scale advantages in emerging markets like Asia Pacific and Latin America.
Risk Factors
Management lowered the full-year gross margin outlook due to approximately $300 million in additional inflationary costs expected during 2026.
Elevated costs for raw materials, packaging, and logistics are pressuring profitability, particularly from higher oil-based inputs and freight expenses.
North America remains the weakest operating region, suffering from delayed product launches, shelf resets, and an increasingly competitive promotional environment.
The stock trades at a premium forward P/E of 23.54 compared to the industry average of 18.42, suggesting limited room for multiple expansion.
Tariff-related pressures and higher raw material costs in North America could continue to weigh on profitability until strategic interventions deliver results.
Colgate-Palmolive (CL) shares are trading near recent highs on the NYSE, supported by fresh institutional buying and a confirmed quarterly dividend. The stock closed at $92.26 on June 29, 2026, representing a gain of roughly 16.8% over the past year, with pre-market trading showing modest strength in the low $90s.
Institutional interest has increased significantly in the first quarter of 2026, highlighted by AMI Asset Management Corp expanding its position by 17.8%. This firm added 75,262 shares to a total stake of 498,079, valued at approximately $42.45 million, which now represents about 2.7% of the fund's portfolio and ranks as its 14th largest holding.
The company recently declared a quarterly dividend payable on August 14, 2026, reinforcing its status as a defensive consumer staples stock for income-focused investors. Financially, Colgate-Palmolive reported earnings per share of $0.97 in its most recent quarter, beating the consensus forecast of $0.94 by $0.03, while revenue grew 8.4% year-over-year.
Analysts collectively maintain an average recommendation of 'Moderate Buy' for the stock, viewing it as a solid defensive name rather than a speculative play. Operationally, the company leverages its global portfolio, including the flagship Colgate toothpaste franchise and the Palmolive brand family in personal and home care, to maintain pricing power and capture growth across both developed and emerging markets.
📈 CL stock closed at $92.26, up 16.8% over the past year.
🏦 AMI Asset Management increased stake by 17.8% to ~$42.45 million.
💰 Quarterly dividend scheduled for payment on August 14, 2026.
📊 EPS of $0.97 beat consensus forecast by $0.03.
📈 Revenue increased 8.4% year-over-year in the latest quarter.
📈 CL stock closed at $92.26 on June 29, 2026, up roughly 16.8% over the past year with extended-hours indications in the low $90s.
🏦 AMI Asset Management Corp increased its position by 17.8% in Q1 2026, adding 75,262 shares to a total stake of 498,079 valued at ~$42.45 million.
💰 The company declared a quarterly dividend scheduled for payment on August 14, 2026, supporting its defensive income profile.
📊 Recent quarterly results showed EPS of $0.97, beating the consensus forecast of $0.94 by $0.03.
📈 Revenue increased by approximately 8.4% year-over-year in the latest quarter, indicating volume growth and pricing power.
🛡️ Brokerages collectively assign an average recommendation of 'Moderate Buy', signaling Wall Street views the shares as solid.
🌍 The company maintains a strong global presence with flagship Colgate oral care products and significant positions in personal care via the Palmolive brand.
🇮🇳 Localized product lines in emerging markets like India and Australia help capture growth while premium positioning supports margins in developed regions.
Bullish Signals
Stock price up 16.8% over past year.
Institutional inflows saw AMI Asset Management add 17.8% stake.
EPS beat expectations at $0.97 vs $0.94 forecast.
Revenue grew 8.4% year-over-year.
Dividend payable August 14, 2026.
Analyst consensus is Moderate Buy.
Bullish Signals
Stock price has appreciated roughly 16.8% over the past year, trading near recent highs on the NYSE.
Significant institutional inflows occurred in Q1 2026, with AMI Asset Management Corp increasing its stake by 17.8%.
The company beat earnings per share expectations, reporting $0.97 versus a consensus forecast of $0.94.
Revenue grew 8.4% year-over-year, demonstrating the ability to offset input cost pressures with volume and pricing power.
A confirmed quarterly dividend payable on August 14, 2026, reinforces its appeal as a defensive income stock.
Analyst consensus is 'Moderate Buy', indicating broad institutional confidence in the company's fundamentals.
Colgate-Palmolive Company (CL) shares have appreciated 16.9% over the past six months, significantly outperforming the Consumer Staples sector and the broader S&P 500. This strong performance is attributed to effective pricing strategies, robust brand equity, a steady innovation pipeline, and ongoing cost-saving initiatives. The company's focus on premiumization in oral care and pet nutrition, combined with its broad geographic footprint, has strengthened growth momentum despite a challenging market environment.
In the first quarter of 2026, Colgate reported accelerated organic sales growth driven by stronger volume trends across all four product categories and most geographic divisions. Management highlighted broad-based demand in emerging markets as a key driver, supported by sustained investments in innovation, advertising, and omnichannel capabilities. The company is also leveraging digital capabilities, artificial intelligence, and data analytics to improve marketing efficiency and consumer targeting, enhancing return on advertising spend while supporting premium innovation.
Despite positive momentum, Colgate faces elevated cost pressures from raw materials, packaging, and logistics, prompting a lower full-year gross margin outlook for 2026. The company expects approximately $300 million in additional inflationary costs due to higher oil-based inputs and freight expenses. North America remains the weakest operating region due to delayed product launches, competitive promotions, and tariff-related pressures. Consequently, Colgate trades at a premium forward P/E of 23.54 compared to the industry average of 18.42, leading analysts to rate it as a 'Hold' (Zacks Rank #3) with new investors advised to wait for a pullback.
📈 CL shares rose 16.9% in six months, outpacing sector and S&P 500 gains.
🚀 Organic sales growth accelerated in Q1 2026 across all product categories.
💡 Company investing in AI and digital capabilities to improve marketing efficiency.
⚠️ Management lowered full-year gross margin outlook due to $300 million inflation costs.
📉 North America faces delays, promotions, and tariff pressures as weakest region.
📈 CL shares rose 16.9% in six months, outpacing the Consumer Staples sector's 9.5% gain and the S&P 500's 7.3% rise.
🚀 Organic sales growth accelerated in Q1 2026 due to stronger volume trends across all four product categories and four of five geographic divisions.
💡 The company is investing in AI, data analytics, and digital capabilities to improve marketing efficiency and consumer targeting.
🌍 Emerging markets, particularly Asia Pacific and Latin America, delivered meaningful volume growth acceleration supported by innovation.
🐾 Hill's Pet Nutrition remains a solid growth engine with organic sales growth despite a soft overall pet food market.
⚠️ Management lowered the full-year gross margin outlook due to approximately $300 million in additional inflationary costs for 2026.
📉 North America is identified as the weakest operating region facing delayed launches, competitive promotions, and tariff pressures.
💰 Colgate trades at a premium forward P/E of 23.54 versus the industry average of 18.42, suggesting limited room for multiple expansion.
🛑 Analysts maintain a Zacks Rank #3 (Hold) rating, advising new investors to wait for a more favorable entry point.
Bullish Signals
CL shares up 16.9% vs S&P 500's 7.3% gain.
Organic sales growth accelerated in Q1 2026.
Investments in AI enhance marketing efficiency and ROAS.
Asia Pacific and Latin America volume growth accelerating.
Risk Factors
Colgate lowered 2026 gross margin outlook due to $300M inflationary costs.
North America remains weakest region facing delays, competition, and tariff pressures.
Stock trades at premium forward P/E of 23.54 vs industry average 18.42.
Higher oil-based inputs driving increased costs weighing on profitability.
Bullish Signals
CL shares have appreciated 16.9% in the past six months, significantly outperforming the industry's 3.2% return and the S&P 500's 7.3% gain.
Organic sales growth accelerated in Q1 2026, supported by stronger volume trends across all four product categories and four of five geographic divisions.
The company is successfully executing an innovation-led growth strategy with investments in AI and digital capabilities enhancing marketing efficiency and return on advertising spend.
Hill's Pet Nutrition delivered solid organic sales growth despite a soft market, reinforcing confidence in the segment's long-term potential.
Asia Pacific and Latin America regions posted meaningful volume growth acceleration driven by innovation and strong in-store performance.
Risk Factors
Colgate lowered its full-year gross margin outlook for 2026 due to approximately $300 million in additional inflationary costs from raw materials, packaging, and logistics.
North America remains the weakest operating region, facing delayed product launches, an increasingly competitive promotional environment, and tariff-related pressures.
The stock trades at a premium forward P/E of 23.54 compared to the industry average of 18.42, indicating that much of the near-term optimism may already be priced in.
Higher oil-based inputs such as resins, petrochemicals, fats, and oils are driving increased costs that could weigh on profitability until strategic interventions deliver results.
Colgate-Palmolive shares are trading steadily on the NYSE as Wall Street analysts refine expectations ahead of the company's next quarterly earnings report. The consensus outlook points toward continued organic sales growth and robust margins, reinforcing the stock's defensive profile within the consumer staples sector.
Recent market data indicates the stock closed at $88.83 on June 22, 2026, with after-hours trading pushing the price to $89.67. By midday on June 23, 2026, alternative data platforms quoted the shares at approximately $89.78, representing a slight gain of about 1.03% against the previous close.
Valuation metrics suggest the company is trading at a trailing price-to-earnings ratio of roughly 34, based on earnings per share of $2.61. This multiple aligns Colgate-Palmolive with other premium consumer peers that command higher valuations due to their stable cash flows and dominant positions in personal care and household product groups.
Colgate-Palmolive generates the majority of its revenue from oral care products, including toothpaste and toothbrushes, alongside a diverse portfolio of personal care ranges and household cleaning brands. These products are sold globally through supermarkets, drugstores, and online channels, underpinning expectations of steady demand for everyday consumer goods.
📈 Analysts expect continued revenue growth and solid EPS in the upcoming quarter.
💰 Stock recently traded at $89.78 USD with premium peer valuation.
📊 Trailing P/E ratio is approximately 34 based on $2.61 EPS.
🏢 MarketBeat lists it as a core S&P 500 consumer sector holding.
🛒 Revenue driven globally by oral care products like toothpaste and brushes.
📈 Analysts expect Colgate-Palmolive to post continued year-on-year revenue growth and solid earnings per share in the upcoming quarter.
💰 The stock recently traded at $89.78 USD, reflecting a valuation consistent with premium consumer staples peers.
📊 The company maintains a trailing price-to-earnings ratio of approximately 34 based on EPS of $2.61.
🏢 MarketBeat data highlights the stock's status as a core holding in the S&P 500 consumer sector.
🛒 Revenue is primarily driven by oral care products like Colgate toothpaste and toothbrushes sold globally.
📅 The next quarterly earnings report date has not been officially scheduled yet.
🌍 Products are distributed through supermarkets, drugstores, and online channels worldwide.
Bullish Signals
Analysts project continued organic sales growth and margin resilience.
Defensive stock with steady demand for everyday products.
Valuation aligns with premium peers indicating stable cash flows.
Bullish Signals
Analysts project continued organic sales growth and margin resilience for the company ahead of the next earnings report.
The stock is viewed as a defensive play within the consumer sector due to steady demand for everyday products.
Valuation multiples align with premium peers, suggesting confidence in stable cash flows and market position.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)